미국 - 영어 - NLM (National Library of Medicine)

e.r. squibb & sons, l.l.c. - hydroxyurea (unii: x6q56qn5qc) (hydroxyurea - unii:x6q56qn5qc) - hydroxyurea 300 mg - droxia is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in patients with sickle cell anemia with recurrent moderate to severe painful crises. droxia is contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of its formulation. droxia can cause fetal harm based on findings from animal studies and the drug’s mechanism of action [see clinical pharmacology (12.1)] . there are no data with droxia use in pregnant women to inform a drug-associated risk. in animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m2 basis (see data) . advise women of the potential risk to a fetus and to avoid becoming pregnant while being treated with droxia. in the u.s. general population, the estimated background risk of major bi

몰타 - 영어 - Medicines Authority

bristol laboratories limited - telmisartan - tablet - telmisartan 20 milligram(s) - agents acting on the renin-angiotensin system

몰타 - 영어 - Medicines Authority

bristol laboratories limited - telmisartan - tablet - telmisartan 40 milligram(s) - agents acting on the renin-angiotensin system

몰타 - 영어 - Medicines Authority

bristol laboratories limited - telmisartan - tablet - telmisartan 80 milligram(s) - agents acting on the renin-angiotensin system

싱가포르 - 영어 - HSA (Health Sciences Authority)

bristol-myers squibb (singapore) pte. ltd. - luspatercept - injection, powder, for solution - luspatercept 25 mg/vial

싱가포르 - 영어 - HSA (Health Sciences Authority)

bristol-myers squibb (singapore) pte. ltd. - luspatercept - injection, powder, for solution - luspatercept 75.0 mg/vial

방글라데시 - 영어 - DGDA (Directorate General of Drug Administration)

bristol pharma ltd. - ascorbic acid + biotin + boron + calcium + chromium + copper + cyanocobalamin + elemental iron + folic acid + iodine + lutein + magnesium + manganese + molybdenum + niacin + nickel + pantothenic acid + phosphorous + pottassium + pyridoxine hydrochloride + riboflavin + selenium + silicon + tin + vanadium + vitamin a + vitamin b1 + vitamin d3 + vitamin e + vitamin k + zinc - tablet - 60 mg + 30 mcg + 150 mcg + 162 mg + 120 mcg + 2 mg + 6 mcg + 18 mg + 400 mcg + 150 mcg + 250 mcg + 100 mg + 2 mg + 75 mcg + 20 m

방글라데시 - 영어 - DGDA (Directorate General of Drug Administration)

bristol pharma ltd. - ranitidine - tablet - 150 mg

방글라데시 - 영어 - DGDA (Directorate General of Drug Administration)

bristol pharma ltd. - tolfenamic acid - tablet - 200 mg

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

bristol laboratories limited - furosemide - tablet - 20 milligram(s) - sulfonamides, plain; furosemide